scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
37 hedge funds and large institutions have $90.1M invested in scPharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
13% more capital invested
Capital invested by funds: $80M → $90.1M (+$10.1M)
12% more funds holding
Funds holding: 33 → 37 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 58.25% → 58.03% (-0.22%)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Belvedere Trading
Chicago,
Illinois
|
+$790K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$338K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$200K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$155K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$1.49M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$411K |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$163K |
| 4 |
Millennium Management
New York
|
-$42.1K |
| 5 |
Renaissance Technologies
New York
|
-$14.2K |
SCPH Hedge Fund Activity: Q1 2022 in Review
37 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2022, worth a combined $90.1M — up 13% from $80M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SCPH positions and 2 closed out — a net gain of 4 holders — while 8 added to existing stakes and 14 trimmed.
The largest buyer was Belvedere Trading, opening a new position worth an estimated $790K. The largest seller was J. Goldman & Co, cutting an estimated $1.49M.
- 37 institutional investors held scPharmaceuticals (SCPH) as of Q1 2022, up from 33 in Q4 2021.
- Funds reported $90.1M of scPharmaceuticals stock for Q1 2022, up 13% quarter-over-quarter.
- 6 funds opened new scPharmaceuticals positions in Q1 2022 and 2 closed out, a net change of +4 holders.
- The largest scPharmaceuticals buyer in Q1 2022 was Belvedere Trading, an estimated $790K added.
- The largest scPharmaceuticals seller in Q1 2022 was J. Goldman & Co, an estimated $1.49M sold.
Based on aggregated 13F filings for Q1 2022.